Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients

• Status: Completed
• Trial end date: 2020-06-30
• Target enrollment: 0
• Participant gender: All

Summary

Background:

The first case of Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were diagnosed in Wuhan, China in 2019. In the first half of 2020 this disease has already converted into a global pandemic. Objectives: To assess the efficacy of Ivermectin in mild cases of COVID-19 patients on the basis of predefined assessment criteria. Study Settings: Fatima Memorial Hospital, Lahore Study Design: Open label randomized control trial. Duration of Study: From 1st May, 2020 to 30th June, 2020.Patients & Methods: Sample size and technique: Sample size was 50 patients; 25 patients were kept in control group and 25 patients were kept in experimental group

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: FMH College of Medicine and Dentistry
• Treatments: Ivermectin

Criteria

Inclusion Criteria:

• All patients diagnosed with COVID-19 infection with positive reverse transcriptase RT-PCR test, who were willing to participate in this study

• Patients having age of 18-75 years

• Patients of both genders male and female

• Patients who had mild symptoms of Corona virus disease and RT- PCR positive for SARS-Cov-2

• Ability to take oral medication and were willing to adhere to the drug intake regimen

Exclusion Criteria:

• Known severe allergic reactions to Ivermectin

• Pregnancy or breastfeeding

• Severe symptoms likely attributed to Cytokine Release Storm

• Malignant diseases

• Chronic kidney disease

• Cirrhosis liver with Child class B or C